Friday, February 26, 2010


Well, 1 week after the report from the US senate asking that Rosiglitazone ( Avandia ), be remove from use in USA, GSK replies in a 30 page white paper to the US senate. Basically, their reply is that GSK was forthcoming in all the information requested, and that the US senate maybe relying too much on the 2007 report by Dr Steve Nissen, whose conclusions were disputed by some experts. GSK is confident that the results of RECORD, due later this year, will show that Rosiglitazone is not associated with any increase incidence of heart attacks. I must say that looking on from here, it may be wise for GSK to volunteerily remove rosiglitazone from the market place. The adverse publicity would certainly affect sales, myself included. I doubt that one study, the RECORD, will safe Rosiglitazone.

No comments: